VAXClinical Trials•globenewswire•
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
Sentiment:Positive (75)
Summary
(VAX) - Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study -
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 10, 2025 by globenewswire